Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.09
AGEN's Cash to Debt is ranked higher than
64% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. AGEN: 3.09 )
AGEN' s 10-Year Cash to Debt Range
Min: 0.24   Max: 106.58
Current: 3.09

0.24
106.58
Equity to Asset -0.13
AGEN's Equity to Asset is ranked lower than
52% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AGEN: -0.13 )
AGEN' s 10-Year Equity to Asset Range
Min: -1.33   Max: 0.92
Current: -0.13

-1.33
0.92
F-Score: 2
Z-Score: -25.82
M-Score: -5.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -820.36
AGEN's Operating margin (%) is ranked higher than
55% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. AGEN: -820.36 )
AGEN' s 10-Year Operating margin (%) Range
Min: -11732.38   Max: -42.23
Current: -820.36

-11732.38
-42.23
Net-margin (%) -987.62
AGEN's Net-margin (%) is ranked higher than
54% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. AGEN: -987.62 )
AGEN' s 10-Year Net-margin (%) Range
Min: -11762.54   Max: -70.95
Current: -987.62

-11762.54
-70.95
ROA (%) -86.33
AGEN's ROA (%) is ranked higher than
53% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. AGEN: -86.33 )
AGEN' s 10-Year ROA (%) Range
Min: -117.51   Max: -32.36
Current: -86.33

-117.51
-32.36
ROC (Joel Greenblatt) (%) -896.95
AGEN's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. AGEN: -896.95 )
AGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -896.95   Max: -182.27
Current: -896.95

-896.95
-182.27
Revenue Growth (%) -21.90
AGEN's Revenue Growth (%) is ranked higher than
64% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. AGEN: -21.90 )
AGEN' s 10-Year Revenue Growth (%) Range
Min: -54.7   Max: 100
Current: -21.9

-54.7
100
EBITDA Growth (%) 2.70
AGEN's EBITDA Growth (%) is ranked higher than
83% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. AGEN: 2.70 )
AGEN' s 10-Year EBITDA Growth (%) Range
Min: -51   Max: 17
Current: 2.7

-51
17
EPS Growth (%) -7.40
AGEN's EPS Growth (%) is ranked higher than
78% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. AGEN: -7.40 )
AGEN' s 10-Year EPS Growth (%) Range
Min: -40   Max: 19.4
Current: -7.4

-40
19.4
» AGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AGEN Guru Trades in Q1 2013

Robert Bruce 233,515 sh (unchged)
» More
Q2 2013

AGEN Guru Trades in Q2 2013

Robert Bruce 233,515 sh (unchged)
» More
Q3 2013

AGEN Guru Trades in Q3 2013

Robert Bruce 233,515 sh (unchged)
» More
Q4 2013

AGEN Guru Trades in Q4 2013

Paul Tudor Jones 28,000 sh (New)
Robert Bruce 233,515 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 27.10
AGEN's P/S is ranked lower than
65% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. AGEN: 27.10 )
AGEN' s 10-Year P/S Range
Min: 4.61   Max: 3564
Current: 27.1

4.61
3564
EV-to-EBIT 0.10
AGEN's EV-to-EBIT is ranked higher than
98% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. AGEN: 0.10 )
AGEN' s 10-Year EV-to-EBIT Range
Min: 10.4   Max: 21.3
Current: 0.1

10.4
21.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.91
AGEN's Price/Median PS Value is ranked higher than
82% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AGEN: 0.91 )
AGEN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 117.31
Current: 0.91

0.2
117.31
Earnings Yield (Greenblatt) 990.40
AGEN's Earnings Yield (Greenblatt) is ranked higher than
97% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. AGEN: 990.40 )
AGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.7   Max: 1119.8
Current: 990.4

4.7
1119.8
Forward Rate of Return (Yacktman) -66.77
AGEN's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. AGEN: -66.77 )
AGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -110.3   Max: -72.9
Current: -66.77

-110.3
-72.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AJ81.Germany
Agenus, Inc. was formerly known as Antigenics Inc. is a biotechnology company incorporated in 1994, which develops and commercializes technologies to treat cancers and infectious diseases, mainly based on immunological approaches. Its advanced product, Oncophage (vitespen), is a patient-specific therapeutic cancer vaccine registered for use in Russia and under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. Oncophage has been tested in Phase 3 clinical trials for the treatment of renal cell carcinoma, the most common type of kidney cancer, and for metastatic melanoma, and it has also been tested in Phase 1 and Phase 2 clinical trials in a range of indications and is currently in a Phase 2 clinical trial in recurrent glioma, a type of brain cancer. The Company's product candidate portfolio includes: QS-21 Stimulon adjuvant, or QS-21, which is used in numerous vaccines under development in trials, some as advanced as Phase 3, for a number of diseases, including hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis, and Aroplatin, a liposomal chemotherapeutic tested in a Phase 1 clinical trial for the treatment of solid malignancies and B-cell lymphomas. The Company's business activities include product research and development, intellectual property prosecution, manufacturing therapeutic vaccines for clinical trials, regulatory and clinical affairs, corporate finance and development activities, market development, and support of its collaborations. The Company faces intense competition from major pharmaceutical companies and specialized biotechnology companies engaged in the development of product candidates directed at cancer and infectious diseases. Several of these companies have products that utilize similar technologies and/or patient-specific medicine techniques, such as Dendreon and Accentia. The Company is also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, and other current and potential future federal, state, or local regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide